The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Quadruplets vs triplets in newly diagnosed myeloma: is more better?
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, Miami, FL, summarizes a talk comparing triplet and quadruplet regimens for the treatment of newly diagnosed multiple myeloma (MM), providing insight into whether combining a greater number of agents results in superior clinical outcomes. When reviewing the data from several trials, Prof. Landgren determined that a fourth drug can be safely added to traditional three-drug backbones to improve clinical outcomes, including progression-free survival (PFS), rate of measurable residual disease (MRD) negativity, and depth of response. Prof. Landgren discusses whether the terms ‘transplant-eligible’ and ‘transplant-ineligible’ may be outdated in the era of novel immunotherapies. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Honoraria: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Membership on an entity’s Board of Directors or advisory committees: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Membership on independent data monitoring committees: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex.
